|

A Retrospective Real-World Study Based on RATIONALE-307

RECRUITINGSponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Actively Recruiting
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
Started2026-02-28
Est. completion2026-12-31
View on ClinicalTrials.gov →

NCT07478809

Summary

The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.

Eligibility

Inclusion Criteria:

* Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion

Exclusion Criteria:

* Patients who had a documented death before study completion in the RATIONALE-307 trial

Conditions3

CancerLung CancerNSCLC (Advanced Non-small Cell Lung Cancer)

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.